Imatinib for chronic myeloid leukaemia: a NICE mess

被引：6

作者：

Barbour, V ^{[1
]}

机构：

[1] Lancet, London WC1X 8RR, England

来源：

LANCET | 2001年 / 358卷 / 9292期

关键词：

D O I：

10.1016/S0140-6736(01)06571-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1478 / 1478

页数：1

共 4 条

[1] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[2] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[3] Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia [J].

Goldman, JM .

LANCET, 2000, 355 (9209) :1031-1032

[4] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

← 1 →